Advertisement
U.S. markets open in 4 hours 14 minutes

Biomerica, Inc. (BMRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.2950-0.0027 (-0.91%)
At close: 04:00PM EDT
0.2950 0.00 (0.00%)
After hours: 07:39PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.2977
Open0.2950
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2810 - 0.2999
52 Week Range0.2400 - 2.1300
Volume92,961
Avg. Volume366,443
Market Cap5.164M
Beta (5Y Monthly)-1.12
PE Ratio (TTM)N/A
EPS (TTM)-0.3700
Earnings DateJan 14, 2025 - Jan 20, 2025
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Biomerica Reports First Quarter Fiscal 2025 Financial Results

    Total Revenue Increases 6% Over Same Period Last Year Cost-Saving Measures Now Implemented, Expected to Reduce Annual Expenses by 16% to 23%, Representing $1.0 to $1.4 Million ReductionBiomerica's At-Home PSA Screening Test Receives Saudi Food and Drug Authority (SFDA) Approval for Early Detection of Prostate Cancer IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today repo

  • GlobeNewswire

    The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer

    - 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi Arabia - Prostate Cancer is the Second Most Common Cancer in Men Globally IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) is pleased to announce that the Saudi Food and Drug Authority (SFDA) has approved the Company's Fortel® Prostate (PSA) Screening Test to be sold and used in the country. This at-home test is designed to empower men with the ability to de